Who are Rosuvastatin and fenofibrate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Atorvastatin and fenofibrate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rosuvastatin-and-fenofibrate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Rosuvastatin and fenofibrate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rosuvastatin and fenofibrate (Rosuvastatin and fenofibrate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin and fibrate combination. Area: Cardiovascular.

marketed Statin and fibrate combination HMG-CoA reductase (rosuvastatin); PPAR-α (fenofibrate) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Rosuvastatin and fenofibrate (Rosuvastatin and fenofibrate) — Gachon University Gil Medical Center. This combination reduces cholesterol and triglycerides by inhibiting HMG-CoA reductase (rosuvastatin) and activating peroxisome proliferator-activated receptors (fenofibrate).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rosuvastatin and fenofibrate TARGET	Rosuvastatin and fenofibrate	Gachon University Gil Medical Center	marketed	Statin and fibrate combination	HMG-CoA reductase (rosuvastatin); PPAR-α (fenofibrate)
Atorvastatin and fenofibrate	Atorvastatin and fenofibrate	The University of Western Australia	marketed	Statin and fibrate combination	HMG-CoA reductase and PPAR-α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin and fibrate combination class)

Gachon University Gil Medical Center · 1 drug in this class
The University of Western Australia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rosuvastatin and fenofibrate — Competitive Intelligence Brief. https://druglandscape.com/ci/rosuvastatin-and-fenofibrate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab